{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:28:54Z","timestamp":1793273334843,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic cancer oligometastatic to the liver represents a distinct subset of advanced disease, presenting a limited number of metastases in a single site. First-line chemotherapy is considered the standard of care, with a poor overall prognosis. However, the optimal strategy for oligometastatic patients presenting response or stability after treatment is unclear. In selected patients, surgical resection is associated with prolonged survival, according to retrospective series. The aim of this randomized clinical trial is to compare the efficacy and safety of surgery versus observation or continuation of chemotherapy in patients with resectable pancreatic cancer oligometastatic to the liver with stable disease or response after first-line chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study is a phase-2 multicentric randomized controlled trial with 1:1 allocation ratio. Patients diagnosed with pancreatic cancer and a limited number (up to 3) of liver metastases, with no evidence of extrahepatic disease, who received systemic chemotherapy as the initial treatment and with disease response or stability after therapy will be considered eligible patients. Patients will be randomized to either Arm A (surgery) or Arm B (observation or continuation of chemotherapy). The primary outcome will be overall survival at two years, with secondary outcomes including progression-free survival, treatment-related adverse events, quality of life and translational analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This randomized controlled trial will evaluate the role of surgery in pancreatic cancer oligometastatic to the liver after response or stability to first-line chemotherapy. While systemic therapy remains the standard of care, selected patients may benefit from surgical resection. By comparing surgery to observation or continuation of chemotherapy, the SONAR trial aims to fill a critical gap in treatment strategies and potentially refine the management of this challenging disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The trial has been registered at ClinicalTrials.gov on 15\/11\/2024 before inclusion of the first patient (NCT06690528).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15183-9","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:34:28Z","timestamp":1768214068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Conversion surgery vs. standard of care in pancreaTic cancer oligometastatic to the liver (SONAR: Surgery in Oligometastatic paNcreatic cAnceR) a randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Riccardo","family":"Guastella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Canitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Padoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Grandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Procaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Carandina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Gringeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marchegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Cillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"15183_CR1","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2468-1253(19)30347-4","volume":"4","author":"GBD 2017 Pancreatic Cancer Collaborators","year":"2019","unstructured":"GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2019;4:934\u201347. https:\/\/doi.org\/10.1016\/S2468-1253(19)30347-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"15183_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00445-1","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP. Pancreatic cancer epidemiology: Understanding the role of lifestyle and inherited risk factors. Nat Reviews Gastroenterol Hepatol. 2021;18:493\u2013502. https:\/\/doi.org\/10.1038\/s41575-021-00445-1.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"key":"15183_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"key":"15183_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0026","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic Adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:439\u201357. https:\/\/doi.org\/10.6004\/jnccn.2021.0026.","journal-title":"J Natl Compr Canc Netw"},{"key":"15183_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326:851\u201362. https:\/\/doi.org\/10.1001\/jama.2021.13027.","journal-title":"JAMA"},{"key":"15183_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0485","volume":"7","author":"M Reyngold","year":"2021","unstructured":"Reyngold M, O\u2019Reilly EM, Varghese AM, Crane CH, Koay EJ, Wuthrick EJ, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer. JAMA Oncol. 2021;7:735\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0485.","journal-title":"JAMA Oncol"},{"key":"15183_CR7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.semcancer.2019.09.019","volume":"60","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Li J, Li D, Zheng S, Wang Y, Fang Y, et al. Tumor biology and multidisciplinary strategies of oligometastasis in Gastrointestinal cancers. Sem Cancer Biol. 2020;60:334\u201343. https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.019.","journal-title":"Sem Cancer Biol"},{"key":"15183_CR8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378\u201382. https:\/\/doi.org\/10.1038\/nrclinonc.2011.44.","journal-title":"Nat Rev Clin Oncol"},{"key":"15183_CR9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1186\/s12885-019-6481-9","volume":"19","author":"AI Damanakis","year":"2019","unstructured":"Damanakis AI, Ostertag L, Waldschmidt D, Koutsoumpas A, Witzigmann H, Diener MK, et al. Proposal for a definition of oligometastatic disease in pancreatic cancer. BMC Cancer. 2019;19:1261. https:\/\/doi.org\/10.1186\/s12885-019-6481-9.","journal-title":"BMC Cancer"},{"key":"15183_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ejso.2016.11.011","volume":"43","author":"T Hackert","year":"2017","unstructured":"Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43:358\u201363. https:\/\/doi.org\/10.1016\/j.ejso.2016.11.011.","journal-title":"Eur J Surg Oncol"},{"key":"15183_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/jso.21602","volume":"102","author":"MC de Jong","year":"2010","unstructured":"de Jong MC, Tsai S, Cameron JL, Wolfgang CL, Hirose K, van Vledder MG, et al. Safety and efficacy of curative intent surgery for periampullary liver metastasis. J Surg Oncol. 2010;102:256\u201363. https:\/\/doi.org\/10.1002\/jso.21602.","journal-title":"J Surg Oncol"},{"key":"15183_CR12","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.3390\/cancers12113402","volume":"12","author":"O De Simoni","year":"2020","unstructured":"De Simoni O, Scarpa M, Tonello M, Cagol M, Alfieri R, Bassi N, et al. Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: which role for conversion surgery? A systematic review and Meta-Analysis. Cancers. 2020;12:3402. https:\/\/doi.org\/10.3390\/cancers12113402.","journal-title":"Cancers"},{"key":"15183_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1089\/pancan.2018.0015","volume":"4","author":"P Kandel","year":"2018","unstructured":"Kandel P, Wallace MB, Stauffer J, Raimondo M, Woodward TA, Gomez V, et al. Survival of patients with oligometastatic pancreatic ductal adenocarcinoma treated with combined modality treatment including surgical resection: A pilot study. J Pancreat Cancer. 2018;4:88\u201394. https:\/\/doi.org\/10.1089\/pancan.2018.0015.","journal-title":"J Pancreat Cancer"},{"key":"15183_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.surg.2016.02.018","volume":"160","author":"M Tachezy","year":"2016","unstructured":"Tachezy M, Gebauer F, Janot M, Uhl W, Bockhorn M, Izbicki JR. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160:136\u201344. https:\/\/doi.org\/10.1016\/j.surg.2016.02.018.","journal-title":"Surgery"},{"key":"15183_CR15","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1245\/s10434-017-5839-8","volume":"24","author":"I Frigerio","year":"2017","unstructured":"Frigerio I, Regi P, Giardino A, Scopelliti F, Girelli R, Bassi C, et al. Downstaging in stage IV pancreatic cancer: A new population eligible for surgery? Ann Surg Oncol. 2017;24:2397\u2013403. https:\/\/doi.org\/10.1245\/s10434-017-5839-8.","journal-title":"Ann Surg Oncol"},{"key":"15183_CR16","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/jhbp.1234","volume":"30","author":"M Nagai","year":"2023","unstructured":"Nagai M, Wright MJ, Ding D, Manandhar R, Kubicky CD, Thomas CR Jr, et al. Oncologic resection of pancreatic cancer with isolated liver metastasis: favorable outcomes in select patients. J Hepato-Biliary-Pancreat Sci. 2023;30:1025\u201335. https:\/\/doi.org\/10.1002\/jhbp.1234.","journal-title":"J Hepato-Biliary-Pancreat Sci"},{"issue":"5","key":"15183_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.surg.2022.04.053","volume":"172","author":"P Bachellier","year":"2022","unstructured":"Bachellier P, Addeo P, Averous G, et al. Resection of pancreatic adenocarcinomas with synchronous liver metastases: A retrospective study of prognostic factors for survival. Surgery. 2022;172(5):1245\u201350. https:\/\/doi.org\/10.1016\/j.surg.2022.04.053.","journal-title":"Surgery"},{"issue":"5","key":"15183_CR18","doi-asserted-by":"publisher","first-page":"e1089","DOI":"10.1097\/SLA.0000000000005481","volume":"277","author":"T Hank","year":"2023","unstructured":"Hank T, Klaiber U, Hinz U, et al. Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer. Ann Surg. 2023;277(5):e1089\u201398. https:\/\/doi.org\/10.1097\/SLA.0000000000005481.","journal-title":"Ann Surg"},{"issue":"6","key":"15183_CR19","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0959-8049(99)00034-6","volume":"35","author":"D Fitzsimmons","year":"1999","unstructured":"Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. Eur J Cancer. 1999;35(6):939\u201341. https:\/\/doi.org\/10.1016\/S0959-8049(99)00034-6.","journal-title":"Eur J Cancer"},{"issue":"12","key":"15183_CR20","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.1245\/s10434-021-09954-4","volume":"28","author":"M Reni","year":"2021","unstructured":"Reni M, Braverman J, Hendifar A, et al. Evaluation of minimal important difference and responder definition in the EORTC QLQ-PAN26 module for assessing health-related quality of life in patients with surgically resected pancreatic adenocarcinoma. Ann Surg Oncol. 2021;28(12):7545\u201354. https:\/\/doi.org\/10.1245\/s10434-021-09954-4.","journal-title":"Ann Surg Oncol"},{"key":"15183_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, et al. RECIST 1.1 \u2013 Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081.","journal-title":"Eur J Cancer"},{"issue":"2","key":"15183_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg"},{"issue":"27","key":"15183_CR23","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.20.01364","volume":"38","author":"DPS Sohal","year":"2020","unstructured":"Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020;38(27):3217\u201330. https:\/\/doi.org\/10.1200\/JCO.20.01364.","journal-title":"J Clin Oncol"},{"issue":"11","key":"15183_CR24","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.7150\/jca.23716","volume":"9","author":"AM Mart\u00edn","year":"2018","unstructured":"Mart\u00edn AM, Hidalgo M, Alvarez R, et al. From first line to sequential treatment in the management of metastatic pancreatic cancer. J Cancer. 2018;9(11):1978\u201388. https:\/\/doi.org\/10.7150\/jca.23716.","journal-title":"J Cancer"},{"issue":"6","key":"15183_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/imj.13810","volume":"48","author":"AMJ Pokorny","year":"2018","unstructured":"Pokorny AMJ, Chin VT, Nagrial AM, Yip D, Chantrill LA. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. Intern Med J. 2018;48(6):637\u201344. https:\/\/doi.org\/10.1111\/imj.13810.","journal-title":"Intern Med J"},{"issue":"2","key":"15183_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020513","volume":"12","author":"Z Li","year":"2023","unstructured":"Li Z, Zhang X, Sun C, et al. Does surgical resection significantly prolong the long-term survival of patients with oligometastatic pancreatic ductal adenocarcinoma? A cross-sectional study based on 18 registries. J Clin Med. 2023;12(2):513. https:\/\/doi.org\/10.3390\/jcm12020513.","journal-title":"J Clin Med"},{"issue":"6","key":"15183_CR27","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.surg.2021.12.029","volume":"171","author":"A Hamad","year":"2022","unstructured":"Hamad A, Underhill J, Ansari A, et al. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: an analysis of the National Cancer Database. Surgery. 2022;171(6):1464\u201370. https:\/\/doi.org\/10.1016\/j.surg.2021.12.029.","journal-title":"Surgery"},{"issue":"13","key":"15183_CR28","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1245\/s10434-022-12385-4","volume":"29","author":"I Frigerio","year":"2022","unstructured":"Frigerio I, Malleo G, de Pastena M, et al. Prognostic factors after pancreatectomy for pancreatic cancer initially metastatic to the liver. Ann Surg Oncol. 2022;29(13):8503\u201310. https:\/\/doi.org\/10.1245\/s10434-022-12385-4.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"15183_CR29","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1245\/s10434-024-15129-8","volume":"31","author":"S Koti","year":"2024","unstructured":"Koti S, Demyan L, Deutsch G, Weiss M. Surgery for oligometastatic pancreatic cancer: defining biologic resectability. Ann Surg Oncol. 2024;31(6):4031\u201341. https:\/\/doi.org\/10.1245\/s10434-024-15129-8.","journal-title":"Ann Surg Oncol"},{"key":"15183_CR30","doi-asserted-by":"publisher","unstructured":"Drouillard T, Gilabert M, Poizat F, Turrini O, Tchakounte C, Moureau-Zabotto L, et al. Multimodal treatment of oligometastatic pancreatic adenocarcinoma: rationale and design of the METAPANC trial, a multicenter, randomized, phase III trial. BMC Cancer. 2025;25:355. https:\/\/doi.org\/10.1186\/s12885-025-13573-7","DOI":"10.1186\/s12885-025-13573-7"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15183-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15183-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15183-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:36:08Z","timestamp":1768473368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15183-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15183"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15183-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the \u201cComitato Etico Territoriale Area Centro-Est Veneto\u201d with reference number 5989\/AO\/24 on 06\/06\/2024. Written informed consent will be obtained from all study participants before enrollment, ensuring their full understanding of the study procedures, potential risks, and benefits. The study adheres to the principles outlined in the Declaration of Helsinki and follows national and institutional ethical guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form (including images or videos) requiring explicit consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}